Just caught something interesting about the vision correction market that's worth paying attention to. STAAR Surgical got FDA approval to expand the age indication for their EVO implantable collamer lenses—basically, ICL meaning these are permanent lens implants that sit inside your eye to correct myopia. The approval extends eligibility from the previous 21-45 age range all the way to 60 years old, which is a pretty significant move.

What caught my eye is the data backing this. Three-year FDA trial results covering 629 eyes showed a solid safety profile—1.25 safety index with virtually zero cases of pupillary block or pigment dispersion. The cataract incidence was minimal at 0.16%. Real-world adoption data is even more telling: surgeons are using EVO ICL in over 70% of procedures for patients with high myopia (-8.0 diopters and above), which suggests a major shift away from laser-based LASIK procedures.

The market context makes this even more interesting. LASIK volumes have cratered nearly 40% over three years, hitting multi-decade lows. Meanwhile, 53% of U.S. vision correction consumers are now actively considering alternatives to LASIK. Management estimates there are 24 million myopic adults in the U.S. who could be candidates, with 8 million specifically in that newly approved 46-60 age segment. That's a massive addressable market that was previously locked out.

From an investment angle, this positions STAA well in a growing sector. The broader intraocular lens market is valued at $5.34 billion in 2026 and expected to grow at 4.72% CAGR through 2035. With declining LASIK demand and strong surgeon preference for lens-based solutions, the expanded age indication should drive meaningful volume growth. The stock already popped 8.4% since the announcement, though it's still down 37.2% over six months while the S&P 500 gained 8.8%.

One thing to note: the company recently appointed Warren Foust and Deborah Andrews as interim co-CEOs effective February 2026, so there's some leadership transition happening in the background while they search for a permanent CEO. Current market cap is around $805.82 million.

The reversible nature of ICL procedures—preserving natural corneal tissue and the crystalline lens—appeals to a lot of patients looking for flexible long-term vision strategies. Combined with the safety data and the expanding addressable market, this approval could be a meaningful catalyst for the refractive surgery space. Worth monitoring if you're tracking the medical device sector.